CLICK HERE FOR BRIUMVI^® (ublituximab-xiiy) PRESCRIBING INFORMATION

A Bold
Approach

Phase I/II Triple Therapy Study of Umbralisib and Ublituximab (U2) Combined with Checkpoint Inhibition in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter’s Transformation (RT)

Started September 23, 2019 345

Read more

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation

Started June 20, 2019 276

Read more

Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-Hodgkin Lymphoma: A Phase 1 Dose Escalation and Expansion Trial

Started February 1, 2019 273

Read more

Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma

Started December 3, 2018 435

Read more

Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation

Started December 2, 2018 320

Read more

Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL

Started June 24, 2017 377

Read more

Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL

Started June 16, 2017 225

Read more

Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma

Started June 15, 2017 372

Read more

Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL

Started June 5, 2017 262

Read more

Safety and Activity of the Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies.

Started June 20, 2015 381

Read more

Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Started June 20, 2015 315

Read more

Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL.

Started June 2, 2015 318

Read more